The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
In the latest session, Hologic, Inc (NASDAQ: HOLX) closed at $74.88 down -0.11% from its previous closing price of $74.96. In other words, the price has decreased by -$0.11 from its previous closing price. On the day, 2.56 million shares were traded. HOLX stock price reached its highest trading level at $75.05 during the session, while it also had its lowest trading level at $74.76.
Ratios:
For a deeper understanding of Hologic, Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.58 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.15. For the most recent quarter (mrq), Quick Ratio is recorded 3.06 and its Current Ratio is at 3.75. In the meantime, Its Debt-to-Equity ratio is 0.52 whereas as Long-Term Debt/Eq ratio is at 0.51.
On November 21, 2025, BNP Paribas Exane Downgraded its rating to Neutral which previously was Outperform but kept the price unchanged to $79.
Evercore ISI Upgraded its In-line to Outperform on October 07, 2025, while the target price for the stock was maintained at $78.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 20 ’25 when Stamoulis Christiana sold 7,402 shares for $73.07 per share. The transaction valued at 540,864 led to the insider holds 47,336 shares of the business.
Stamoulis Christiana bought 7,402 shares of HOLX for $540,864 on Oct 20 ’25. On Sep 22 ’25, another insider, MACMILLAN STEPHEN P, who serves as the Chairman, President and CEO of the company, sold 138,358 shares for $66.97 each. As a result, the insider received 9,266,118 and left with 1,234,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HOLX now has a Market Capitalization of 16703149056 and an Enterprise Value of 17112043520. As of this moment, Hologic,’s Price-to-Earnings (P/E) ratio for their current fiscal year is 30.16, and their Forward P/E ratio for the next fiscal year is 14.98. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.75. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.07 while its Price-to-Book (P/B) ratio in mrq is 3.30. Its current Enterprise Value per Revenue stands at 4.173 whereas that against EBITDA is 12.665.
Stock Price History:
The Beta on a monthly basis for HOLX is 0.72, which has changed by 0.045467257 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, HOLX has reached a high of $75.34, while it has fallen to a 52-week low of $51.90. The 50-Day Moving Average of the stock is 0.40%, while the 200-Day Moving Average is calculated to be 12.41%.
Shares Statistics:
For the past three months, HOLX has traded an average of 3.46M shares per day and 2239450 over the past ten days. A total of 222.56M shares are outstanding, with a floating share count of 219.51M. Insiders hold about 1.60% of the company’s shares, while institutions hold 98.65% stake in the company. Shares short for HOLX as of 1765756800 were 3669918 with a Short Ratio of 1.06, compared to 1763078400 on 3885730. Therefore, it implies a Short% of Shares Outstanding of 3669918 and a Short% of Float of 2.17.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is $1.1, with high estimates of $1.14 and low estimates of $1.05.
Analysts are recommending an EPS of between $4.64 and $4.47 for the fiscal current year, implying an average EPS of $4.56. EPS for the following year is $5.0, with 15.0 analysts recommending between $5.18 and $4.75.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $1.07B this quarter.It ranges from a high estimate of $1.09B to a low estimate of $1.05B. As of . The current estimate, Hologic, Inc’s year-ago sales were $1.02BFor the next quarter, 10 analysts are estimating revenue of $1.05B. There is a high estimate of $1.07B for the next quarter, whereas the lowest estimate is $1.04B.
A total of 18 analysts have provided revenue estimates for HOLX’s current fiscal year. The highest revenue estimate was $4.32B, while the lowest revenue estimate was $4.24B, resulting in an average revenue estimate of $4.28B. In the same quarter a year ago, actual revenue was $4.1BBased on 16 analysts’ estimates, the company’s revenue will be $4.51B in the next fiscal year. The high estimate is $4.57B and the low estimate is $4.42B.
